British Startup Trendlox Launches Crowdfunding Campaign for New 2-in-1 Laser Therapy and TENS Device

Image: https://www.abnewswire.com/upload/2025/03/bb5471bbb4bbf08ddffc041a050ce2e2.jpg

Trendlox, a health tech startup based in the UK, is introducing a new approach to pain management with the launch of its 2-in-1 Laser Therapy Device with TENS Function. This device combines low-level laser therapy (LLLT) and transcutaneous electrical nerve stimulation (TENS) to offer a non-invasive, drug-free solution to pain relief and recovery. To support the development and production of the device, Trendlox has launched a crowdfunding campaign on Indiegogo [https://igg.me/at/trendlox1], which went live on March 2, 2025.

The Trendlox 2-in-1 device combines two clinically proven therapies in a single, compact design. The laser therapy function (LLLT) is known for promoting cell regeneration, reducing inflammation, and accelerating healing, making it useful for those dealing with chronic pain, sports injuries, or muscle tension. The TENS function blocks pain signals to the brain while stimulating the production of endorphins, providing natural pain relief without relying on medication.

Image: https://www.abnewswire.com/upload/2025/03/eace3cc908c71f9642e757654891b66e.jpg

This device is designed for home use, as well as physiotherapy clinics and sports recovery, giving individuals the ability to manage pain and promote healing independently. Trendlox aims to provide a more accessible and effective alternative to traditional pain relief methods, focusing on helping people recover more quickly and live with less discomfort.

"Millions of people suffer from chronic pain daily, and it can be difficult to find a solution that doesn't rely on medication," said Martins Okonkwo, Founder of Trendlox. "We've created a device that combines two proven therapies in one easy-to-use tool so people can take charge of their own pain management and recovery."

The crowdfunding campaign on Indiegogo offers backers the opportunity to secure early-bird discounts on the device, as well as other perks, such as early delivery and VIP support. The company is hopeful that this campaign will help them bring the product to market and give those who need it an affordable and effective option for managing pain.

Image: https://www.abnewswire.com/upload/2025/03/e82fa337cb26c071f3429c8015b431bf.jpg

Trendlox has developed the 2-in-1 Laser Therapy Device with a focus on ease of use and practicality, aiming to provide an alternative to invasive procedures and medication. By offering this solution, Trendlox hopes to empower users to make decisions about their health and wellness, improving their quality of life with a simple yet effective tool.

The crowdfunding campaign is live now on Indiegogo at https://igg.me/at/trendlox1.

For further details on how to back the project or to learn more about the product, visit the company's website at http://www.trendlox.com. For media inquiries, partnerships, or interviews, please contact info@trendlox.co.uk

About Trendlox:

Trendlox is a UK-based health tech startup focused on creating solutions to improve pain management and recovery. By combining advanced technology with user-friendly design, Trendlox aims to empower individuals to take charge of their health

Media Contact
Company Name: Trendlox
Contact Person: Martins Okonkwo
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=british-startup-trendlox-launches-crowdfunding-campaign-for-new-2in1-laser-therapy-and-tens-device]
City: London
Country: United Kingdom
Website: http://www.trendlox.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.